title: [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
abstract: OBJECTIVE
  To analyse resistance to imatinib therapy, efficacy and safety of dasatinib.
  
  
  METHODS
  A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage received dasatinib for 9-30 months (median 30 months) to September 2008.
  
  
  RESULTS
  Lethal outcomes during dasatinib treatment were absent. To September 2008, 16 (89%) patients were alive, 2 (11%) patients died of the disease progression after dasatinib discontinuation. A complete clinicohematological response was observed in all the patients. Major cytogenetic, complete cytogenetic, major molecular, complete molecular responses were achieved in 12 (67%), 10 (55%), 7 (39%) and 5 (28%) patients, respectively. Hematological and non-hematological toxicity occurred in 9 (50%) patients. Now 12 (67%) patients continue dasatinib treatment, in 6 (33%) patients the drug was discontinued.
  
  
  CONCLUSIONS
  The results from trials in Russian Hematological Research Center are the same as in the international study. Dasatinib is effective and well tolerated therapeutic option for imatinib-resistant patients with a chronic phase of CML.
authors.forename: O Iu
authors.initials: OIu
authors.lastname: Vinogradova
authors.forename: A G
authors.initials: AG
authors.lastname: Turkina
authors.forename: A V
authors.initials: AV
authors.lastname: Vorontsova
authors.forename: E Iu
authors.initials: EIu
authors.lastname: Chelysheva
authors.forename: G A
authors.initials: GA
authors.lastname: Gusarova
authors.forename: S V
authors.initials: SV
authors.lastname: Kuznetsov
authors.forename: S R
authors.initials: SR
authors.lastname: Goriacheva
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolova
authors.forename: E M
authors.initials: EM
authors.lastname: Abakumov
authors.forename: O V
authors.initials: OV
authors.lastname: Stakhina
authors.forename: E V
authors.initials: EV
authors.lastname: Domracheva
authors.forename: A V
authors.initials: AV
authors.lastname: Misiurin
authors.forename: N D
authors.initials: ND
authors.lastname: Khoroshko
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D000069439:Dasatinib; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib